Literature DB >> 8574972

Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines.

J Rubin Grandis1, Q Zeng, D J Tweardy.   

Abstract

Retinoic acid (RA) has been shown to be effective in eradicating premalignant lesions and preventing second primary malignancies in patients cured of squamous cell carcinoma of the head and neck (SCCHN) in clinical trials. The basis for this effect is unclear. We have previously demonstrated that messenger RNA from tumor growth factor-alpha (TGF-alpha) and its receptor, the epidermal growth factor (EGFR), is unregulated in tumors and histologically normal mucosal samples from patients with SCCHN compared with control normal mucosa from patients without cancer, implicating this ligand-receptor pair in an autocrine growth pathway early in the molecular pathogenesis of this disease. In this report, we examined the hypothesis that the action of RA on the mucosa of the upper aerodigestive tract is mediated via downregulation of steady-state TGF-alpha and/or EGFR mRNA levels. Following exposure to all-trans-RA, a series of SCCHN cell lines demonstrated a 35.4% reduction in TGF-alpha mRNA expression (P = 0.022) and 58.5% reduction in EGFR mRNA (P = 0.0027). Nuclear run-on analysis indicated that the RA-mediated reduction of TGF-alpha and EGFR steady-state mRNA levels was a result of decreased gene transcription. These results suggest that the clinical effects of RA in SCCHN patients may be due to a downmodulation of TGF-alpha and EGFR mRNA production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8574972     DOI: 10.1038/nm0296-237

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  17 in total

1.  Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Authors:  Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Authors:  Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

3.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

4.  A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.

Authors:  K Szepeshazi; A V Schally; G Halmos; N Lamharzi; K Groot; J E Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 5.  Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

Authors:  Mark E Sharafinski; Robert L Ferris; Soldano Ferrone; Jennifer R Grandis
Journal:  Head Neck       Date:  2010-10       Impact factor: 3.147

Review 6.  Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.

Authors:  Robert B Diasio; Jeanne Fourie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

8.  Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells.

Authors:  Huafei Zou; Sufi M Thomas; Zhen-Wen Yan; Jennifer R Grandis; Andreas Vogt; Lu-Yuan Li
Journal:  FASEB J       Date:  2008-10-02       Impact factor: 5.191

9.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Authors:  J R Grandis; S D Drenning; A Chakraborty; M Y Zhou; Q Zeng; A S Pitt; D J Tweardy
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 10.  Combination of radiotherapy with EGFR antagonists for head and neck carcinoma.

Authors:  Juliette Thariat; Gokcen Yildirim; Kathryn A Mason; Adam S Garden; Luka Milas; K Kian Ang
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.